Carmell Therapeutics received U.S. Patent No. 9,364,503, broadly covering the use of plasma-based materials (PBMs) as vehicles for delivering antimicrobials, analgesics, anti-inflammatory drugs and other drugs and proteins. This new patent brings Carmell’s total portfolio to 8 U.S. and 9 foreign issued patents. Additional U.S. and foreign patents remain pending.
PBMs are manufactured from pooled human blood plasma that is treated to inactivate viruses, then freeze-dried into powder and plasticized to create pastes, putties, scaffolds, plugs and screws. Carmell’s first product in development is REPAIR™ Putty to augment bone fractures. The new patent focuses on novel PBMs that can deliver antimicrobials locally.
Studies have shown that use of REPAIR plasma-based bone putty reduced infections, sped bone healing and promoted rapid wound closure in the treatment of open tibia fractures.
Sources: Carmell Therapeutics, ORTHOWORLD Inc.
Carmell Therapeutics received U.S. Patent No. 9,364,503, broadly covering the use of plasma-based materials (PBMs) as vehicles for delivering antimicrobials, analgesics, anti-inflammatory drugs and other drugs and proteins. This new patent brings Carmell’s total portfolio to 8 U.S. and 9 foreign issued patents. Additional U.S. and foreign...
Carmell Therapeutics received U.S. Patent No. 9,364,503, broadly covering the use of plasma-based materials (PBMs) as vehicles for delivering antimicrobials, analgesics, anti-inflammatory drugs and other drugs and proteins. This new patent brings Carmell’s total portfolio to 8 U.S. and 9 foreign issued patents. Additional U.S. and foreign patents remain pending.
PBMs are manufactured from pooled human blood plasma that is treated to inactivate viruses, then freeze-dried into powder and plasticized to create pastes, putties, scaffolds, plugs and screws. Carmell’s first product in development is REPAIR™ Putty to augment bone fractures. The new patent focuses on novel PBMs that can deliver antimicrobials locally.
Studies have shown that use of REPAIR plasma-based bone putty reduced infections, sped bone healing and promoted rapid wound closure in the treatment of open tibia fractures.
Sources: Carmell Therapeutics, ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
